Tuberculosis
Tuberculosis (TB) is a contagious and potentially serious infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also affect other parts of the body, such as the kidneys, spine, and brain.
TB spreads through the air when an infected individual coughs, sneezes, or speaks, releasing tiny droplets containing the bacteria into the air. When a person inhales these droplets, they can become infected with TB. However, it’s important to note that not everyone infected with the bacteria develops active TB. In many cases, the immune system is able to keep the bacteria in check, causing the infection to remain latent.
Latent TB infection means that the bacteria are present in the body but are inactive and do not cause any symptoms. People with latent TB are not contagious and cannot spread the disease to others. However, if the immune system becomes weakened, such as due to certain medical conditions or medications, latent TB can become active.
This magazine contains content which is gathered, validated, categorized, and supplied using a novel big data cyberinfrastructure technology that continually learns about Tuberculosis.
-
Publication date: Jan 14, 2025 Single nucleotide variations (SNVs) and polymorphisms (SNPs) are characteristic biomarkers ...
-
Micronutrient status and risk of Mycobacterium tuberculosis infection in Indonesian tuberculosis case contacts.
Publication date: Jan 16, 2025 Certain micronutrient levels have been associated with the risk of ... -
Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
Publication date: Jan 16, 2025 The impact of heteroresistance on tuberculosis (TB) treatment outcomes is ... -
New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).
Publication date: Jan 16, 2025 Omadacycline is a novel antimicrobial belonging to the tetracycline class. ... -
Macrolide resistance due to erm(55).
Publication date: Jan 16, 2025 Antimicrobial resistance (AMR) is a global threat. The identification and ... -
As resistant tuberculosis rises, GSK says trial backs novel antibiotic
Publication date: Jan 16, 2025 With cases of drug-resistant tuberculosis on the rise again around ... -
Perceptions and experiences of directly observed treatment in tuberculosis: insights from a mixed-methods cross-sectional study.
Publication date: Nov 11, 2024 The demanding nature and psychosocial burdens of directly observed treatment ... -
Clinical and epidemiological characterization of patients with cutaneous tuberculosis treated at a referral center in the Brazilian Amazon: case series.
Publication date: Jan 14, 2025 Cutaneous tuberculosis is a rare form of the disease that ... -
Identifying plasma exosome antigens as a potential diagnostic biomarker for tuberculosis disease.
Publication date: Jan 14, 2025 Exosome is a small extracellular vesicle with a diameter of ... -
Potential of Mycobacterium tuberculosis Type II NADH-Dehydrogenase in Antitubercular Drug Discovery.
Publication date: Jan 15, 2025 The type II NADH-dehydrogenase enzyme in Mycobacterium tuberculosis plays a ... -
The next generation of drug resistant tuberculosis drug design.
Publication date: Jan 15, 2025 Concepts Keywords Drug drug-discovery Future drug-resistance Med Mycobacterium tuberculosis Resistant ... -
Amplification-free detection of Mycobacterium tuberculosis using CRISPR-Cas12a and graphene field-effect transistors.
Publication date: Jan 15, 2025 Current molecular tests for tuberculosis (TB), such as whole genome ... -
Targeting InhA in drug-resistant Mycobacterium tuberculosis: potent antimycobacterial activity of diaryl ether dehydrozingerone derivatives.
Publication date: Jan 15, 2025 Tuberculosis (TB) remains a major global threat, with 10 million ... -
Screening, Discovery, and Optimization of the Natural Antitubercular Chlorflavonin from a Marine-Derived Fungal Library.
Publication date: Jan 15, 2025 Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis (Mtb), is ... -
Interventions to Maintain HIV/AIDS, Tuberculosis, and Malaria Service Delivery During Public Health Emergencies in Low- and Middle-Income Countries: Protocol for a Systematic Review.
Publication date: Jan 15, 2025 Although existing disease preparedness and response frameworks provide guidance about ... -
Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.
Publication date: Jan 15, 2025 Co-existent pulmonary tuberculosis and lung cancer (PTB-LC) represent a unique ... -
Single-cell analysis reveals Mycobacterium tuberculosis ESX-1-mediated accumulation of permissive macrophages in infected mouse lungs.
Publication date: Jan 17, 2025 Mycobacterium tuberculosis (MTB) ESX-1, a type VII secretion system, is ... -
Mixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathy.
Publication date: Mar 01, 2025 Nontuberculous mycobacteria (NTM) are increasingly recognized opportunistic pathogens found ubiquitously ... -
Structural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity.
Publication date: Feb 01, 2025 Tuberculosis (TB) remains a significant global health challenge, with multidrug-resistant ... -
Discovery of acetohydroxyacid synthase inhibitors as anti-tuberculosis lead compounds from natural products.
Publication date: Feb 01, 2025 Acetohydroxy acid synthase (AHAS) is a key enzyme that catalyzes ... -
SYSTEMS AND NETWORK BIOLOGY ANALYSIS COMBINED WITH MACHINE LEARNING IDENTIFIES KEY IMMUNE RESPONSE PROFILES AND POTENTIAL CORRELATES OF PROTECTION FOR THE M72/AS01E TUBERCULOSIS VACCINE.
Publication date: Jan 13, 2025 Tuberculosis claims around 1.5 million lives annually. The M72/AS01E vaccine ...